Abstract
Estrogen exerts beneficial effects on the brain throughout life. Studies demonstrate that estrogen is neuroprotective and that reduced brain estrogen activity may influence the clinical course of Alzheimers disease (AD). Changes in levels of estrogen receptors have been detected in postmortem brain tissue of AD patients. Very little is known about the relationship between clinical stage and levels of estrogen receptors in postmortem brain. We hypothesized that estrogen receptor levels would be related to severity of cognitive impairment assessed proximate to death. Western blotting was used to quantify ER-α and ER-β in nuclear, cytosolic, and crude membrane fractions of superior frontal cortex from 25 AD patients. Multiple linear regression analyses adjusted for age, sex, and education showed a significant linear relationship between Mini-Mental State Examination score (MMSE) and wild-type nuclear ER-α (â = 5.463, p = 0.03), but none between MMSE and wild-type nuclear ER-β (â = 2.29, p = 0.36). We incidentally observed additional higher and lower molecular mass bands for ER-α in study subjects. Additional experiments performed on frontal cortex nuclear fractions prepared from subjects enrolled in a different study confirmed that these same bands are present in female and males with and without AD. Together our data show a relationship between wild-type ER-α and level of cognitive impairment in AD, and also suggest the possibility that variant isoforms of ER-α may be present in frontal cortex of patients with and without AD.
Keywords: Cognition, postmortem brain tissue, dementia, neuroprotection, splice variants, isoforms
Current Alzheimer Research
Title: Levels of Estrogen Receptors α and β in Frontal Cortex of Patients with Alzheimers Disease: Relationship to Mini-Mental State Examination Scores
Volume: 5 Issue: 1
Author(s): Jeremiah F. Kelly, Julia L. Bienias, Avni Shah, Kathleen A. Meeke, Julie A. Schneider, Edwin Soriano and David A. Bennett
Affiliation:
Keywords: Cognition, postmortem brain tissue, dementia, neuroprotection, splice variants, isoforms
Abstract: Estrogen exerts beneficial effects on the brain throughout life. Studies demonstrate that estrogen is neuroprotective and that reduced brain estrogen activity may influence the clinical course of Alzheimers disease (AD). Changes in levels of estrogen receptors have been detected in postmortem brain tissue of AD patients. Very little is known about the relationship between clinical stage and levels of estrogen receptors in postmortem brain. We hypothesized that estrogen receptor levels would be related to severity of cognitive impairment assessed proximate to death. Western blotting was used to quantify ER-α and ER-β in nuclear, cytosolic, and crude membrane fractions of superior frontal cortex from 25 AD patients. Multiple linear regression analyses adjusted for age, sex, and education showed a significant linear relationship between Mini-Mental State Examination score (MMSE) and wild-type nuclear ER-α (â = 5.463, p = 0.03), but none between MMSE and wild-type nuclear ER-β (â = 2.29, p = 0.36). We incidentally observed additional higher and lower molecular mass bands for ER-α in study subjects. Additional experiments performed on frontal cortex nuclear fractions prepared from subjects enrolled in a different study confirmed that these same bands are present in female and males with and without AD. Together our data show a relationship between wild-type ER-α and level of cognitive impairment in AD, and also suggest the possibility that variant isoforms of ER-α may be present in frontal cortex of patients with and without AD.
Export Options
About this article
Cite this article as:
Kelly F. Jeremiah, Bienias L. Julia, Shah Avni, Meeke A. Kathleen, Schneider A. Julie, Soriano Edwin and Bennett A. David, Levels of Estrogen Receptors α and β in Frontal Cortex of Patients with Alzheimers Disease: Relationship to Mini-Mental State Examination Scores, Current Alzheimer Research 2008; 5 (1) . https://dx.doi.org/10.2174/156720508783884611
DOI https://dx.doi.org/10.2174/156720508783884611 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Neurotrophin Propeptides: Biological Functions and Molecular Mechanisms
Current Protein & Peptide Science The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies
Medicinal Chemistry Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents New Trends in Fiber-Optic Chemical and Biological Sensors
Current Analytical Chemistry Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Possible Physiopathological Effects of the Transglutaminase Activity on the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemistry of SPOT Synthesis for the Preparation of Peptide Macroarrays on Cellulose Membranes
Mini-Reviews in Organic Chemistry Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review of Natural and Modified Betulinic, Ursolic and Echinocystic Acid Derivatives as Potential Antitumor and Anti-HIV Agents
Mini-Reviews in Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Synthesis, Biological Activity of Thiazolidinones Bearing Indoline Moiety and Isatin Based Hybrids
Mini-Reviews in Organic Chemistry